Oxetacaine

Oxetacaine
Systematic (IUPAC) name

2,2'-(2-hydroxyethylimino)bis [N-(1,1-dimethyl-2- phenylethyl)-N-methylacetamide]
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, topical
Pharmacokinetic data
Half-life	1 hour
Identifiers
CAS Registry Number	126-27-2^N
ATC code	C05AD06
PubChem	CID 4621
ChemSpider	4460^Y
UNII	IP8QT76V17^Y
KEGG	D01152^Y
ChEMBL	CHEMBL127592^Y
Chemical data
Formula	C₂₈H₄₁N₃O₃
Molecular mass	467.643 g/mol
SMILES O=C(N(C(C)(C)Cc1ccccc1)C)CN(CCO)CC(=O)N(C(Cc2ccccc2)(C)C)C
InChI InChI=1S/C28H41N3O3/c1-27(2,19-23-13-9-7-10-14-23)29(5)25(33)21-31(17-18-32)22-26(34)30(6)28(3,4)20-24-15-11-8-12-16-24/h7-16,32H,17-22H2,1-6H3 ^Y Key:FTLDJPRFCGDUFH-UHFFFAOYSA-N ^Y
N (what is this?) (verify)

Oxetacaine (INN, also known as oxethazaine) is a potent local anesthetic. It is administered orally (usually in combination with an antacid) for the relief of pain associated with peptic ulcer disease or esophagitis. It is also used topically in the management of hemorrhoid pain. Oral oxetacaine preparations are available in several countries, including India, South Africa, Japan and Brazil, but not the United States.

Unlike most local anesthetics, oxetacaine is active even in strongly acidic conditions.^[1]

References

↑ Seifter J, Glassman JM, Hudyma GM (1962). "Oxethazaine and related congeners: a series of highly potent local anesthetics". Proc Soc Exp Biol Med 109: 664–8. doi:10.3181/00379727-109-27300. PMID 13910333.

External links

Strocain Prescribing information from Eisai Co.

Anesthetics : Local anesthetics (primarily sodium channel blockers) (N01B)

Esters by acid

Aminobenzoic	Benzocaine Butacaine Butamben Chloroprocaine Dimethocaine Lucaine Meprylcaine Metabutethamine Metabutoxycaine Orthocaine Propoxycaine Procaine (Novocaine) Proxymetacaine Risocaine Tetracaine

Benzoic	Amylocaine 3-(p-Fluorobenzoyloxy)tropane Cocaine Cyclomethycaine α-Eucaine β-Eucaine Hexylcaine Isobucaine Piperocaine

Amides

Articaine
Bupivacaine # / Levobupivacaine / Ropivacaine
Butanilicaine
Carticaine
Dibucaine
Etidocaine
Lidocaine #
Mepivacaine
Prilocaine
Trimecaine

Combinations

Lidocaine / prilocaine
Anesthetic / vasoconstrictor
Iontocaine

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Index of the peripheral nervous system

Description	Anatomy Nerves cranial trigeminal cervical brachial lumbosacral plexus somatosensory spinal autonomic Physiology reflexes proteins neurotransmitters transporters Development neurotrophins

Disease	Autonomic Congenital Injury Neoplasms and cancer Other Symptoms and signs eponymous

Treatment	Procedures Local anesthetics

Vasoprotectives (C05)

Antihemorrhoidals for topical use

corticosteroids	Hydrocortisone Prednisolone Betamethasone Fluorometholone Fluocortolone Dexamethasone Fluocinolone acetonide Fluocinonide

local anesthetics	Lidocaine Tetracaine Benzocaine Dibucaine Procaine Oxetacaine Pramocaine

other	Tribenoside

Antivaricose therapy

heparins or heparinoids for topical use	Organo-heparinoid Sodium apolate Heparin Pentosan polysulfate

sclerosing agents for local injection	Monoethanolamine oleate Polidocanol Inverted sugar syrup Sodium tetradecyl sulfate Phenol

other	Calcium dobesilate

Capillary stabilising agents

bioflavonoids	Rutoside Monoxerutin Diosmin Troxerutin Hidrosmin

other	Tribenoside Etamsylate

Index of the circulatory system

Description	Anatomy Arteries head and neck arms chest abdomen legs Veins head and neck arms chest abdomen and pelvis legs Development Cells Physiology proteins

Disease	Congenital Neoplasms and cancer Lymphatic vessels Injury Vasculitis Other Symptoms and signs eponymous

Treatment	Procedures Drugs beta blockers channel blockers diuretics nonsympatholytic vasodilatory antihypertensives peripheral vasodilators renin–angiotensin system sympatholytic antihypertensives vasoprotectives